Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetesGlobeNewsWire · Oct 15, 2026
Immunocore Hits Enrollment Target in Kimmtrak Label Expansion StudyZacks Investment Research · Sep 15, 2026
Immunocore Holdings plc (IMCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha · Sep 15, 2026
Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanomaGlobeNewsWire · Sep 14, 2026
Immunocore to present at upcoming investor conferencesGlobeNewsWire · Sep 1, 2026
Bank of America Corp DE Trims Stock Position in Immunocore Holdings PLC Sponsored ADR $IMCRDefense World · Aug 27, 2026Immunocore Holdings plc, a biotechnology firm established in 1999 and based in Abingdon, United Kingdom, has reached the commercial stage in its mission to create pioneering immunotherapies. The company's development pipeline addresses a range of serious conditions, including various cancers, infectious diseases, and autoimmune disorders. Its currently marketed product, KIMMTRAK, offers a treatment option for patients with uveal melanoma that is either unresectable or has metastasized.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$0.01 | -$0.02 | Miss |
| May 6, 2026 | -$0.26 | $0.25 | Beat |
| Feb 25, 2026 | -$0.28 | -$0.60 | Miss |
| Nov 6, 2025 | -$0.30 | $0.02 | Beat |
| Aug 7, 2025 | -$0.21 | -$0.20 | Beat |
| May 7, 2025 | -$0.35 | $0.10 | Beat |